{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T06:00:01Z","timestamp":1790316001876,"version":"4.1.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2023A1515012477"],"award-info":[{"award-number":["2023A1515012477"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2025A1515010689"],"award-info":[{"award-number":["2025A1515010689"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Rituximab (RTX) is the first-line treatment for primary membranous nephropathy (pMN), yet approximately one-third of patients exhibit refractory disease. Evidence supporting RTX combined with low-dose glucocorticoids for refractory pMN remains limited. This study aimed to evaluate the efficacy and safety of this combination regimen in a rituximab-na\u00efve refractory cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Thirty-six adults with refractory pMN received rituximab plus low-dose glucocorticoids (prednisone equivalent). The primary endpoint was clinical remission at 24 months, analyzed in both the intention-to-treat (ITT,\n                      <jats:italic>n<\/jats:italic>\n                      = 36) and per-protocol (PP,\n                      <jats:italic>n<\/jats:italic>\n                      = 22) populations. Sensitivity analyses included a worst-case scenario (assuming all dropouts were non-remitters).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-five patients had evaluable 12-month outcomes, and 26 of them achieved remission (74.3%, with 25.7% achieving complete remission and 48.6% partial remission). By 24 months, the remission rate was 95.5% (21\/22) in the per-protocol analysis and 91.67% in the intention-to-treat analysis, compared with 58.3% (21\/36) in the worst-case scenario. We found no statistically significant difference in cumulative remission rates between serum PLA2R-positive and PLA2R-negative groups, or between renal tissue PLA2R-positive and PLA2R-negative groups. All 25 patients positive for anti-PLA2R antibodies showed a decreasing antibody trend after treatment, and 80.0% (20\/25) achieved complete antibody clearance (antibody titer &amp;lt;20 RU\/mL). Adverse events occurred in 37.1% (13\/35) of patients, with 11.4% (4\/35) of patients developing serious infections. No serious malignant events or fatal events were reported during the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this cohort of patients with refractory pMN, rituximab combined with low-dose glucocorticoids achieved high short-term remission rates, and no safety signals were observed that would preclude further investigation. However, given the uncontrolled study design, repeated RTX dosing, and residual confounding from prior immunosuppression, we cannot draw definitive conclusions on whether adding glucocorticoids offers incremental benefit compared with rituximab monotherapy. The high remission rates observed in this study may also be attributable to repeated rituximab exposure and residual effects of prior immunosuppression. Furthermore, this empirical combination regimen was not designed to test whether glucocorticoids have a direct additive or synergistic effect. Larger randomized controlled trials are therefore warranted to confirm these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1894444","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:32:15Z","timestamp":1790314335000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Rituximab with low-dose glucocorticoids for treating refractory membranous nephropathy: a prospective single-center cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Youqi","family":"Li","sequence":"first","affiliation":[{"name":"Department of Nephrology, NHC Key Laboratory of Clinical Nephrology (Sun Yat-Sen University) and Guangdong Provincial Key Laboratory of Nephrology, The First Affiliated Hospital, Sun Yat-sen University","place":["Guangzhou, China"]},{"name":"Department of Nephrology, Huizhou Central People\u2019s Hospital","place":["Huizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, NHC Key Laboratory of Clinical Nephrology (Sun Yat-Sen University) and Guangdong Provincial Key Laboratory of Nephrology, The First Affiliated Hospital, Sun Yat-sen University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Jiao","sequence":"additional","affiliation":[{"name":"Department of Nephrology, NHC Key Laboratory of Clinical Nephrology (Sun Yat-Sen University) and Guangdong Provincial Key Laboratory of Nephrology, The First Affiliated Hospital, Sun Yat-sen University","place":["Guangzhou, China"]},{"name":"Department of Nephrology, The Third Hospital of Changsha","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwen","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, NHC Key Laboratory of Clinical Nephrology (Sun Yat-Sen University) and Guangdong Provincial Key Laboratory of Nephrology, The First Affiliated Hospital, Sun Yat-sen University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianbo","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Nephrology, NHC Key Laboratory of Clinical Nephrology (Sun Yat-Sen University) and Guangdong Provincial Key Laboratory of Nephrology, The First Affiliated Hospital, Sun Yat-sen University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boxun","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Huizhou Central People\u2019s Hospital","place":["Huizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junbing","family":"He","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Jieyang People\u2019s Hospital","place":["Jieyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Nephrology, NHC Key Laboratory of Clinical Nephrology (Sun Yat-Sen University) and Guangdong Provincial Key Laboratory of Nephrology, The First Affiliated Hospital, Sun Yat-sen University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghua","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, NHC Key Laboratory of Clinical Nephrology (Sun Yat-Sen University) and Guangdong Provincial Key Laboratory of Nephrology, The First Affiliated Hospital, Sun Yat-sen University","place":["Guangzhou, China"]},{"name":"Department of Nephrology, Jieyang People\u2019s Hospital","place":["Jieyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1093\/ndt\/gfaf127","article-title":"Urinary rituximab loss and rate of treatment failure in membranous nephropathy","volume":"41","author":"Allinovi","year":"2025","journal-title":"Nephrol. Dialysis, Transplantation"},{"key":"B2","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1093\/ndt\/gfab323","article-title":"Proteinuria selectivity index predicts response to rituximab in adults with minimal change disease and focal segmental glomerulosclerosis","volume":"37","author":"Allinovi","year":"2022","journal-title":"Nephrol. Dial. Transpl."},{"key":"B3","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1111\/j.1440-1797.2007.00822.x","article-title":"Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome","volume":"12","author":"Chan","year":"2007","journal-title":"Nephrol. Carlt."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.3346\/jkms.2018.33.e74","article-title":"The effect of mycophenolate mofetil versus cyclosporine as combination therapy with low dose corticosteroids in high-risk patients with idiopathic membranous nephropathy: a multicenter randomized trial","volume":"33","author":"Choi","year":"2018","journal-title":"J. Korean Med. Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s40259-021-00487-6","article-title":"Factors influencing infusion-related reactions following dosing of reference rituximab and PF-05280586, a rituximab biosimilar","volume":"35","author":"Courville","year":"2021","journal-title":"BioDrugs"},{"key":"B6","doi-asserted-by":"publisher","first-page":"932","DOI":"10.2215\/CJN.01180307","article-title":"Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy","volume":"2","author":"Cravedi","year":"2007","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for severe membranous nephropathy: a 6-Month trial with extended Follow-Up","volume":"28","author":"Dahan","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/ndt\/gfad156","article-title":"Multitarget therapy with a corticosteroid, cyclosporine and mycophenolate mofetil for idiopathic membranous nephropathy: a prospective randomized controlled trial","volume":"39","author":"Duan","year":"2023","journal-title":"Nephrol. Dial. Transpl."},{"key":"B9","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1053\/j.ajkd.2008.04.013","article-title":"Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial","volume":"52","author":"Dussol","year":"2008","journal-title":"Am. J. Kidney Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.kint.2020.10.014","article-title":"The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy","volume":"99","author":"Fernandez-Juarez","year":"2021","journal-title":"Kidney Int."},{"key":"B12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/nejmoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/sj.ki.5002628","article-title":"Rituximab treatment of idiopathic membranous nephropathy","volume":"73","author":"Fervenza","year":"2008","journal-title":"Kidney Int."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.2215\/CJN.05080610","article-title":"Rituximab therapy in idiopathic membranous nephropathy: a 2-year study","volume":"5","author":"Fervenza","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"572863","DOI":"10.3389\/fphar.2020.572863","article-title":"Rituximab hypersensitivity: from clinical presentation to management","volume":"11","author":"Fouda","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1681\/ASN.2013040430","article-title":"Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy","volume":"25","author":"Hoxha","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1681\/ASN.2008070786","article-title":"Role of rituximab therapy in glomerulonephritis","volume":"21","author":"Jayne","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"Clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1548679","DOI":"10.3389\/fneph.2025.1548679","article-title":"Efficacy and safety of rituximab for membranous nephropathy in adults: a meta-analysis of RCT","volume":"5","author":"Mao","year":"2025","journal-title":"Front. Nephrology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1093\/ndt\/gfw251","article-title":"Low-dose rituximab is poorly effective in patients with primary membranous nephropathy","volume":"32","author":"Moroni","year":"2017","journal-title":"Nephrol. Dial. Transpl."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2612448","DOI":"10.1080\/0886022x.2025.2612448","article-title":"Long-term real-world outcomes of rituximab in primary membranous nephropathy: a 154-patient cohort study from China","volume":"48","author":"Qi","year":"2026","journal-title":"Ren. Failure"},{"key":"B22","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.autrev.2016.12.005","article-title":"Calcineurin inhibitors versus cyclophosphamide for idiopathic membranous nephropathy: a systematic review and meta-analysis of 21 clinical trials","volume":"16","author":"Qiu","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"B23","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.ekir.2017.02.004","article-title":"Two-year Follow-up study of membranous nephropathy treated with tacrolimus and corticosteroids Versus cyclical corticosteroids and cyclophosphamide","volume":"2","author":"Ramachandran","year":"2017","journal-title":"Kidney Int. Rep."},{"key":"B24","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/S0140-6736(02)11042-7","article-title":"Rituximab for idiopathic membranous nephropathy","volume":"360","author":"Remuzzi","year":"2002","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41572-021-00303-z","article-title":"Membranous nephropathy","volume":"7","author":"Ronco","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1097\/01.asn.0000071511.35221.b3","article-title":"Rituximab in idiopathic membranous nephropathy: a one-year prospective study","volume":"14","author":"Ruggenenti","year":"2003","journal-title":"J. Am. Soc. Nephrol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1681\/ASN.2012020181","article-title":"Rituximab in idiopathic membranous nephropathy","volume":"23","author":"Ruggenenti","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1681\/ASN.2014070640","article-title":"Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy","volume":"26","author":"Ruggenenti","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nrneph.2017.92","article-title":"Treatment of membranous nephropathy: time for a paradigm shift","volume":"13","author":"Ruggenenti","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1002\/art.22046","article-title":"Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment","volume":"54","author":"Smith","year":"2006","journal-title":"Arthritis Rheum."},{"key":"B31","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1681\/asn.2020071091","article-title":"Rituximab or cyclophosphamide in the treatment of membranous nephropathy: the RI-CYCLO randomized trial","volume":"32","author":"Scolari","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.2215\/CJN.11791018","article-title":"High-dose rituximab and early remission in PLA2R1-Related membranous nephropathy","volume":"14","author":"Seitz-Polski","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1770916","DOI":"10.3389\/fmolb.2026.1770916","article-title":"Optimized RTX strategy plus structured glucocorticoid tapering for primary membranous nephropathy: a multicenter propensity score-matched cohort study","volume":"13","author":"Sun","year":"2026","journal-title":"Front. Molecular Biosciences"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1681\/ASN.2016091022","article-title":"Safety of rituximab compared with steroids and cyclophosphamide for idiopathic membranous nephropathy","volume":"28","author":"van den Brand","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1093\/ndt\/gfx295","article-title":"Rituximab for non-responsive idiopathic membranous nephropathy in a Chinese cohort","volume":"33","author":"Wang","year":"2018","journal-title":"Nephrol. Dial. Transpl."},{"key":"B36","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1681\/ASN.2016010093","article-title":"Long-term exposure to air pollution and increased risk of membranous nephropathy in China","volume":"27","author":"Xu","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1093\/ndt\/gfae230","article-title":"Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy","volume":"40","author":"Xu","year":"2025","journal-title":"Nephrol. Dial. Transpl."},{"key":"B38","doi-asserted-by":"publisher","first-page":"111718","DOI":"10.1016\/j.intimp.2024.111718","article-title":"Optimized rituximab regimen versus recommended regimen for idiopathic membranous nephropathy: a single-center retrospective cohort study","volume":"130","author":"Yan","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/kjm2.12098","article-title":"Efficacy and safety of tacrolimus-based treatment for nephrotic idiopathic membranous nephropathy in young adults: a retrospective study","volume":"35","author":"Zhang","year":"2019","journal-title":"Kaohsiung J. Med. Sci."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1156470","DOI":"10.3389\/fimmu.2023.1156470","article-title":"Efficacy and safety of rituximab for primary membranous nephropathy with different clinical presentations: a retrospective study","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Immunol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1894444\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:32:17Z","timestamp":1790314337000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1894444\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":40,"alternative-id":["10.3389\/fphar.2026.1894444"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1894444","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"article-number":"1894444"}}